Trial Profile

A Phase I Open Label First in Human Dose Escalation and Expansion Study of the Bispecific Anti-Mucin 1 - Epidermal Growth Factor Receptor Antibody Drug Conjugate M1231 as a Single Agent in Participants With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs M 1231 (Primary)
Indications Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors EMD Serono Research & Development Institute

06 Jul 2023 Status changed from active, no longer recruiting to completed.
06 Dec 2022 Status changed from recruiting to active, no longer recruiting.
22 Nov 2021 According to a Merck & Co media release, efficacy expansions into late-stage non-small cell lung cancer and esophageal squamous cell carcinoma are expected to begin in 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com